Stock·NYSE·Healthcare
AbbVie Inc. (ABBV)
- Market cap
- $504.30B
- P/E
- 80.06
- Dividend yield
- 2.42%
- Street target
- $285.00median of 30 analysts
- 52-week range
- $190.75 $291.40
The short version
Where ABBV stands today, in four lines, and what CleaRank Financial AI makes of it.
ABBV at a glance
AbbVie Inc. (ABBV): Buy, 69/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($262.45 and $233.95).
- Earnings ABBV beat estimates in 4 of its last 4 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $30.0M and made no open-market purchases over the last 18 months.
- Valuation P/E of 80.1 against 31.9 for the Healthcare sector: a premium to peers (+151%).
Figures as of October 16, 2026.
CleaRank Financial AI
CleaRank rates AbbVie Inc. (ABBV) Buy, with a model score of 69/100.
The trend lifts the score most: the price is 21.99% above its 200-day average and 8.74% above its 50-day average, and the 50-day average is 12.18% above the 200-day. Valuation holds it back most: the P/E of 80.06 is 151.0% above the sector median (a premium to peers) and the P/S of 7.78 is 128.8% above the sector median. The 50-day average stands at $262.45 and the 200-day at $233.95. Over the past year the price rose 25.79%.
Only on CleaRank
Figures we compute ourselves from ABBV's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $285.38 is 8.7% above the 50-day simple moving average of $262.45.Price above its 200-day average ›
The price is 22.0% above the 200-day simple moving average of $233.95.50-day average above the 200-day ›
The 50-day average ($262.45) is 12.2% above the 200-day average ($233.95), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 94% of its 52-week range, between $190.75 and $291.40.
ABBV share price
Pick a period: each tab shows how far ABBV has moved over it, to the last close.
Today's trading
Where ABBV sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 80.06 is 151.0% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 7.78 is 128.8% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $6.3B on revenue of $64.4B, a net margin of 9.7%.Beat estimates in most recent reports ›
ABBV beat the EPS estimate in 4 of its last 4 reports.Pays a dividend ›
The trailing dividend yield is 2.42%, or $6.92 a share a year.
Key statistics
The headline figures for ABBV.
As of October 16, 2026, ABBV trades at $285.38, with a market value of $504.30B, a P/E ratio of 80.06 and a dividend yield of 2.42%.
What the numbers say
CleaRank Financial AI's reading of ABBV's valuation, growth and risks.
ABBV trades at 80.06 times trailing earnings, which is 151.0% above the Healthcare sector median of 31.9. The Peer Benchmarking card labels that P/E a premium to peers. On sales, the P/S of 7.78 is 128.8% above the sector median of 3.4. AbbVie Inc. (ABBV) carries a market value of $504.3B.
Revenue grew 10.20% over the latest year, which is 2.1 percentage points ahead of the 8.1% median for Healthcare. ABBV turns sales into profit at a net margin of 9.80% and an operating margin of 40.04%, alongside a return on equity of -129.68%, below the sector median of 7.3%. It also reports a trailing dividend yield of 2.42% ($6.92 a share a year).
AbbVie Inc. (ABBV) reported EPS of $3.65 in its most recent earnings report, released on July 31, 2026. The figure topped the analysts' estimate by 1.11%. Even so, the stock fell 2.33% in the next session.
Across its last 4 reports, ABBV beat the estimate every time, but beats have not guaranteed gains: the stock fell the next day after 2 of them.
Valuation leaves less margin for error: the P/E of 80.06 is 151.0% above the sector median, a premium to peers on the Peer Benchmarking card. On a typical day the price of ABBV shifts by 1.23%, the 30-day standard deviation of its daily returns. Over the last 18 months, insider sales totalled $30.0M with no open-market purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
ABBV against the Healthcare sector
How ABBV compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ABBV trades at a significant premium to sector peers (+151%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 6, 2025, ABBV has gained 52.5% against a gain of 31.4% for XLV.
Performance against XLV
ABBV and the Healthcare sector fund over the same days.
Revenue and earnings
How much ABBV sells, and how much of it becomes profit.
Revenue growth: Revenue grew 8.6% in FY2025 to $61.2B, from $56.3B a year earlier.
Profit margin: The net margin was 6.9% in FY2025, down from 7.6% the year before.
Profitable: ABBV earned $4.2B in FY2025.
Earnings reality check
Did ABBV beat what analysts expected, and how did the stock react?
Earnings record: ABBV beat the analyst estimate in 4 of the last 4 quarters.
Market reaction: The stock fell in the first session after 2 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 31, 2026after close | $3.61 | $3.65 | +1.11% | -2.33% | -1.95% |
| Feb 4, 2026after close | $2.65 | $2.71 | +2.26% | +0.88% | +1.74% |
| Oct 31, 2025after close | $1.78 | $1.86 | +4.49% | -2.79% | +0.51% |
| Jul 31, 2025after close | $2.91 | $2.97 | +2.06% | +3.28% | +5.21% |
As of October 16, 2026, ABBV has beaten the analyst EPS estimate in 4 of its last 4 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on July 31, 2026, came in 1.11% above the estimate and the stock moved -2.33% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 71.0, in overbought territory.RSI above 50 ›
An RSI of 71.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of ABBV
The score, the reasoning behind it, and what could move the price next.
AbbVie Inc. (ABBV) is trading at $285.38, above both of its main moving averages. The price sits 8.74% above its 50-day average of $262.45 and 21.99% above its 200-day average of $233.95. It is at 94% of its 52-week range, 2.07% below the 52-week high of $291.40. The 50-day average is 12.18% above the 200-day average, which means the shorter-term trend is ahead of the longer one.
Momentum is strong for ABBV: the 14-day RSI sits at 71.0, which is in overbought territory, and the MACD line is positive. The price has climbed 12.14% over the past three months, 36.95% over the past six months and 25.79% over the past year, and every period on the chart shows a gain.
Earnings beat ›
The July 31, 2026 report beat the EPS estimate by 1.11%, and the share price fell 2.33% in the first session after it.
Source: Earnings report, July 31, 2026
Rating reaffirmed ›
UBS kept its Neutral rating on October 9, 2026.
Source: Analyst action, UBS, October 9, 2026
- Two levels matter most right now. The first is the 52-week high at $291.40, just above the price. The second is the 20-day EMA at $271.93, just below it.
- With the 14-day RSI at 71.0, ABBV is in the overbought zone and the MACD line is positive. Readings above 70, or below 30, are generally treated as a sign of stretched momentum.
- ABBV beat estimates in 4 of the last 4 reports, yet after the July 31, 2026 report the share price fell 2.33% in the first session.
ABBV trades above its 50-day and 200-day moving averages ($262.45 and $233.95), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 20-day EMA at $271.93.
The 52-week high at $291.40 is the next level overhead. With the RSI in overbought territory, a pause would not end the trend by itself, but a drop back out of the bullish zone would show momentum fading.
Technical indicators
Momentum and trend for ABBV, from its daily closes.
As of October 16, 2026, with ABBV at $285.38, its 14-day RSI is 71.0 (overbought territory), its 50-day simple moving average is $262.45 and its 200-day is $233.95.
Calculated by CleaRank on daily closes as of October 16, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What ABBV moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 16, 2026, ABBV's 1-year correlation of daily returns is +0.16 with S&P 500 (SPY), +0.04 with Nasdaq 100 (QQQ), -0.04 with Bitcoin (BTC) and +0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
24 of 30 analysts rate it a buy or strong buy, 5 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $285.00 is 0.1% below the price.More buy ratings than three months ago ›
24 of 30 rate it a buy now, against 24 of 31 three months ago.
ABBV Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 9, 2026 | UBS | Maintains | Neutral |
| Oct 9, 2026 | Guggenheim | Reiterates | Buy |
| Oct 8, 2026 | JP Morgan | Maintains | Overweight |
| Oct 8, 2026 | Cantor Fitzgerald | Maintains | Overweight |
| Oct 7, 2026 | Morgan Stanley | Maintains | Overweight |
| Oct 6, 2026 | Scotiabank | Maintains | Sector Outperform |
As of October 16, 2026, 30 Wall Street analysts cover ABBV: 24 rate it a buy or strong buy, 5 a hold and 1 a sell or strong sell. Their 12-month price targets range from $200.00 to $328.00, with a median of $285.00, 0.1% below the price of $285.38.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ABBV trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from ABBV's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ABBV tends to move, against the market and on its own.
The long record
ABBV's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.23% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 42.9%, from March 2018 to August 2019, regained by November 2020.Most 1-year holds ended higher ›
84% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $70,412, against $42,525 in the S&P 500 (SPY).
ABBV Drawdowns & Recovery
As of October 16, 2026, ABBV's worst peak-to-trough fall over the last 10 years with dividends reinvested was -42.9% (March 2018 to August 2019); it regained that peak by November 2020, 15 months after the low, and 84% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ABBV in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ABBV beat the S&P 500 over this period: $70,412 against $42,525.
A $10,000 investment in ABBV in October 2016 would be worth about $70,412 today with dividends reinvested, compared with about $42,525 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ABBV, and which have not.
Strongest month, November: an average of +7.85%, up in 8 of 10 years.
Weakest month, March: an average of -1.96%, up in 4 of 10 years.
This month, October: has averaged -1.06%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ABBV's strongest calendar month has been November (average +7.85%, up in 8 of 10 years) and its weakest March (average -1.96%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ABBV, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in ABBV today could grow to about $25,097 by 2036 in the base case, with a 90th-percentile outcome near $72,947 and a 10th-percentile outcome around $8,635. The simulation models price only; at today's 2.42% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
ABBV Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $412 for ABBV by 2030 in the base case, from $285 today (1.4x over 4 years). The 10th-percentile path ends near $210. These are outcomes of a Monte Carlo simulation run on ABBV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $223 | $313 | $438 | |
| 2028 | $213 | $343 | $553 | |
| 2029 | $210 | $376 | $675 | |
| 2030 | $210 | $412 | $810 | |
| 2031 | $213 | $452 | $961 |
Method: a lognormal simulation of ABBV's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
ABBV insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought ABBV shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 16, 2026, ABBV insiders reported 6 open-market sales worth $30.0M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Nicholas Donoghoe
Officer
|
Sell | 32.7K | $8.2M |
| Aug 14, 2026 | Nicholas Donoghoe
Officer
|
Option | 32.7K | $2.6M |
| May 8, 2026 | Roxanne Schuh Austin
Director
|
Grant | 1.1K | - |
| May 8, 2026 | William H L Burnside
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Jennifer L Davis
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Thomas J Falk
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Thomas C Freyman
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Brett J Hart
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Melody B Meyer
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Susan E Quaggin
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Edward J Rapp
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Rebecca B. Roberts
Director
|
Grant | 1.1K | - |
| May 8, 2026 | Frederick H Waddell
Director
|
Grant | 1.1K | - |
| Mar 4, 2026 | David Ryan Purdue
Officer
|
Sell | 5.2K | $1.2M |
| Mar 2, 2026 | Perry C. Siatis
General Counsel
|
Sell | 18.7K | $4.4M |
| Feb 25, 2026 | Perry C. Siatis
General Counsel
|
Sell | 22.4K | $5.1M |
| Feb 25, 2026 | Perry C. Siatis
General Counsel
|
Option | 22.4K | $3.9M |
| Feb 18, 2026 | Demetris D Crum
Officer
|
Grant | 2.5K | - |
| Feb 18, 2026 | Nicholas Donoghoe
Officer
|
Grant | 29.1K | - |
| Feb 18, 2026 | Robert A. Michael
Chief Executive Officer
|
Grant | 82.4K | - |
| Feb 18, 2026 | Scott T. Reents
Chief Financial Officer
|
Grant | 48.8K | - |
| Feb 18, 2026 | Azita Saleki-Gerhardt
Chief Operating Officer
|
Grant | 36.8K | - |
| Feb 18, 2026 | Perry C. Siatis
General Counsel
|
Grant | 33.5K | - |
| Feb 18, 2026 | Jeffrey Ryan Stewart
Officer
|
Grant | 53.7K | - |
| Feb 18, 2026 | Roopal Thakkar
Officer
|
Grant | 18.1K | - |
| Aug 12, 2025 | Azita Saleki-Gerhardt
Chief Operating Officer
|
Sell | 42.4K | $8.4M |
| Aug 12, 2025 | Azita Saleki-Gerhardt
Chief Operating Officer
|
Option | 42.4K | $2.3M |
| Aug 5, 2025 | Nicholas Donoghoe
Officer
|
Sell | 13.3K | $2.6M |
| May 9, 2025 | Robert J Alpern
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Roxanne Schuh Austin
Director
|
Grant | 1.2K | - |
| May 9, 2025 | William H L Burnside
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Jennifer L Davis
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Thomas J Falk
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Thomas C Freyman
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Brett J Hart
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Melody B Meyer
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Susan E Quaggin
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Edward J Rapp
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Rebecca B. Roberts
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Glenn Fletcher Tilton
Director
|
Grant | 1.2K | - |
| May 9, 2025 | Frederick H Waddell
Director
|
Grant | 1.2K | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 16, 2026.